Characteristics of the chronic Chagas disease patients and control individuals.

<p>CCD: chronic Chagas disease patients; NC: without heart involvement patients, CCC: chronic chagasic cardiopathy patients.</p><p>*mixed population (white + mulatto + black) = 165 controls and 131 patients</p><p>Characteristics of the chronic Chagas disease patients and control individuals.</p

Distribution of <i>KIR</i> genes in healthy controls, chronic Chagas disease patients and in groups of patients with and without heart involvement.

<p>CCD: chronic Chagas disease patients, NC: without heart involvement patients, CCC: chronic chagasic cardiopathy patients.</p><p>^<b>a</b><i>P</i> = 0.017; <i>Pc</i> = 0.27; OR = 0.41; 95% CI = 0.20–0.83 (CCC vs Controls)</p><p>Distribution of <i>KIR</i> genes in healthy controls, chronic Chagas disease patients and in groups of patients with and without heart involvement.</p

Distribution of KIR and their respective HLA ligands in Chagas disease patients and controls.

<p>CCD: chronic Chagas disease patients; NC: without heart involvement patients, CCC: chronic chagasic cardiopathy patients.</p><p>^<b>a</b><i>P</i> = 0.036; <i>Pc</i> = 0.108; OR = 0.43; 95% CI = 0.24–0.75 (CCD vs Controls)</p><p>^<b>b</b><i>P</i> = 0.037; <i>Pc</i> = 0.10; OR = 0.54; 95% CI = 0.31–0.94 (CCD vs Controls)</p><p>^<b>c</b><i>P</i> = 0.031; <i>Pc</i> = 0.093; OR = 0.23; 95% CI = 0.04–0.89 (CCC vs NC)</p><p>Bw4 = <i>HLA-A*23</i>,<i>*24</i>,<i>*32; HLA-B</i>,<i>*13</i>,<i>*27</i>,<i>*44</i>,<i>*51</i>,<i>*52</i>,<i>*53</i>,<i>*57</i>,<i>*58</i></p><p>Group C1 = <i>HLA-C*01</i>,<i>*03</i>,<i>*07</i>,<i>*08</i>,<i>*12</i>,<i>*14</i>,<i>*16</i></p><p>Group C2 = <i>HLA-C*02</i>,<i>*04</i>,<i>*05</i>,<i>*06</i>,<i>*07</i>,<i>*15</i>,<i>*17</i>,<i>*18</i></p><p>Distribution of KIR and their respective HLA ligands in Chagas disease patients and controls.</p

Distribution of activating KIR plus inhibitory KIR and their respective ligands in chronic Chagas disease and controls.

<p>CCD: chronic Chagas disease patients; NC: without heart involvement patients, CCC: chronic chagasic cardiopathy patients.</p><p>^<b>a</b><i>P</i> = 0.020; <i>Pc</i> = 0.040; OR = 2.14; 95% CI = 1.25–7.88 (CCD vs Controls)</p><p>^<b>b</b><i>P</i> = 0.0002; <i>Pc</i> = 0.0004; OR = 6.64; 95% CI = 2.30–18.60 (CCC vs Controls)</p><p>^<b>c</b><i>P</i> = 0.010; <i>Pc</i> = 0.020; OR = 3.97; 95% CI = 1.34–11.79 (CCC vs NC)</p><p>^<b>d</b><i>P</i> = 0.050; <i>Pc</i> = 0.100; OR = 1.06; 95% CI = 1.1–6.9 (CCD vs Controls)</p><p>^<b>e</b><i>P</i> = 0.040; <i>Pc</i> = 0.080; OR = 3.64; 95% CI = 1.12–11.91 (CCC vs NC)</p><p>^<b>f</b><i>P</i> = 0.004; <i>Pc</i> = 0.008; OR = 5.02; 95% CI = 1.71–14.73 (CCC vs Controls)</p><p>^<b>g</b><i>P</i> = 0.036; <i>Pc</i> = 0.144; OR = 0.54; 95% CI = 0.31–0.94 (CCD vs Controls)</p><p>Distribution of activating KIR plus inhibitory KIR and their respective ligands in chronic Chagas disease and controls.</p